These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

769 related items for PubMed ID: 20687088

  • 1. Deferasirox for managing transfusional iron overload in people with sickle cell disease.
    Meerpohl JJ, Antes G, Rücker G, Fleeman N, Niemeyer C, Bassler D.
    Cochrane Database Syst Rev; 2010 Aug 04; (8):CD007477. PubMed ID: 20687088
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Deferasirox for managing iron overload in people with thalassaemia.
    Bollig C, Schell LK, Rücker G, Allert R, Motschall E, Niemeyer CM, Bassler D, Meerpohl JJ.
    Cochrane Database Syst Rev; 2017 Aug 15; 8(8):CD007476. PubMed ID: 28809446
    [Abstract] [Full Text] [Related]

  • 4. Deferasirox for managing transfusional iron overload in people with sickle cell disease.
    Meerpohl JJ, Schell LK, Rücker G, Motschall E, Fleeman N, Niemeyer CM, Bassler D.
    Cochrane Database Syst Rev; 2014 Jun 04; 5(5):CD007477. PubMed ID: 24893174
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Deferasirox for managing iron overload in people with myelodysplastic syndrome.
    Meerpohl JJ, Antes G, Rücker G, Fleeman N, Motschall E, Niemeyer CM, Bassler D.
    Cochrane Database Syst Rev; 2010 Nov 10; (11):CD007461. PubMed ID: 21069694
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Deferasirox for managing iron overload in people with myelodysplastic syndrome.
    Meerpohl JJ, Schell LK, Rücker G, Fleeman N, Motschall E, Niemeyer CM, Bassler D.
    Cochrane Database Syst Rev; 2014 Oct 28; 2014(10):CD007461. PubMed ID: 25348770
    [Abstract] [Full Text] [Related]

  • 10. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
    Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P, Files B, Hassell K, Kelly P, Wilson F, Bernaudin F, Forni GL, Okpala I, Ressayre-Djaffer C, Alberti D, Holland J, Marks P, Fung E, Fischer R, Mueller BU, Coates T, Deferasirox in Sickle Cell Investigators.
    Br J Haematol; 2007 Feb 28; 136(3):501-8. PubMed ID: 17233848
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
    Vichinsky E, Torres M, Minniti CP, Barrette S, Habr D, Zhang Y, Files B, study CICL670A2201 investigators.
    Am J Hematol; 2013 Dec 28; 88(12):1068-73. PubMed ID: 23946212
    [Abstract] [Full Text] [Related]

  • 12. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
    Geneen LJ, Dorée C, Estcourt LJ.
    Cochrane Database Syst Rev; 2023 Mar 06; 3(3):CD012349. PubMed ID: 36877640
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.
    McLeod C, Fleeman N, Kirkham J, Bagust A, Boland A, Chu P, Dickson R, Dundar Y, Greenhalgh J, Modell B, Olujohungbe A, Telfer P, Walley T.
    Health Technol Assess; 2009 Jan 06; 13(1):iii-iv, ix-xi, 1-121. PubMed ID: 19068191
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN, Kontoghiorghes GJ.
    Drug Des Devel Ther; 2016 Jan 06; 10():465-81. PubMed ID: 26893541
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.